World Health Organization Calls for Drug Decriminalization and Broad Drug Policy Reforms
Recommendations Also Include Harm Reduction Measures and Banning Compulsory Treatment
Statement from Ethan Nadelmann: U.S. Drug Policy Should Reflect WHO’s Health-Based Recommendations
In a report published earlier this month, the World Health Organization (WHO) made a clear call for broad drug policy reforms, including decriminalization of drug use, harm reduction practices such as syringe exchange and opioid substitution therapy, and a ban on compulsory treatment for people who use drugs. This report by the United Nations’ leading health agency focuses on best practices to prevent, diagnose and treat HIV among key populations.
“It’s good to see the WHO come out so strongly for decriminalizing drugs and rejecting compulsory treatment for people who use drugs,’ said Ethan Nadelmann, Executive Director of the Drug Policy Alliance. “Its recommendations, grounded as they are in science and public health, drive home the need for fundamental reforms in U.S. drug policies, in particular the growing reliance on drug courts to ‘treat’ people arrested for drug possession.”
In a section titled “Good practice recommendations concerning decriminalization”, the WHO report makes the following recommendations:
- Countries should work toward developing policies and laws that decriminalize injection and other use of drugs and, thereby, reduce incarceration.
- Countries should work toward developing policies and laws that decriminalize the use of clean needles and syringes (and that permit NSPs [needle and syringe programmes]) and that legalize OST [opioid substitution therapy] for people who are opioid-dependent.
- Countries should ban compulsory treatment for people who use and/or inject drugs.
This follows on the heels of a report released in March by a key working group of the United Nations Office on Drugs and Crime (UNODC) discouraging criminal sanctions for drug use. The recommendations of the working group – which included Nora Volkow, head of the U.S. National Institute on Drug Abuse (NIDA) – highlight that “criminal sanctions are not beneficial” in addressing the spectrum of drug use and misuse.
In 2016, the United Nations General Assembly will hold a special session on drugs (UNGASS) – an initiative proposed in 2012 by the then-president of Mexico, Felipe Calderon – in order to conduct a comprehensive review of the successes and failures of international drug control policy. Whereas the previous UNGASS in 1998 was dominated by rhetorical calls for a “drug-free world” and concluded with unrealistic goals regarding illicit drug production, the forthcoming UNGASS will undoubtedly be shaped by recommendations such as those in the WHO report.
Last year, Uruguay followed on the heels of Colorado and Washington State and became the first country to legally regulate marijuana for recreational purposes. In June, the West Africa Commission on Drugs, initiated by former United Nations Secretary General Kofi Annan and chaired by former Nigerian President Olusegun Obasango, called for drug decriminalization and for treating drug use as a health issue. This was followed by an announcement by the Jamaican Minister of Justice that the Jamaican Cabinet had approved a proposal to decriminalize the possession of up to two ounces of marijuana and the decriminalization of marijuana use for religious, scientific and medical purposes. And earlier this month, the Heads of Government of the Caribbean Community (CARICOM), agreed to establish a commission to review marijuana policy in the region in order to assess the need for reforms to marijuana laws.
The WHO recommendations are consistent with the long-standing policy objectives and mission of the Drug Policy Alliance, as well as with a surprisingly broad and rapidly-emerging coalition of stakeholders who are calling for drug decriminalization, including the American Public Health Association, International Red Cross, Organization of American States, NAACP, Human Rights Watch, National Latino Congreso, and the Global Commission on Drug Policy.
Contact: Tony Newman (646) 335-5384 or Hannah Hetzer (917) 701-7060